Loading
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Previous close
$0.4999
+$0.0149 · +3.07%
After-hours
$0.49
−$0.0099 · -1.98%
Oct 7, 7:50 PM ET
Regular session · ET · Market data may be delayed.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Day range
Current $0.4999
52-week range
Current $0.4999
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
46
Fair Value
Sentiment
56
Mixed
Risk
70
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Day range
Current $0.4999
52-week range
Current $0.4999
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.39B USD | 4.11M USD | 15.49M USD | 10.07M USD | 10.59M USD |
| Selling, general, and administrative | 6.97B USD | 6.44M USD | 5.45M USD | 4.48M USD | 5.27M USD |
| Operating expenses | 9.36M USD | 10.56M USD | 20.9M USD | 14.42M USD | 15.77M USD |
| Interest income | 182.23K USD | 45.9K USD | 210.39K USD | 135.9K USD | 75.85K USD |
| Interest expense | 785.93K USD | 29.83K USD | 30.59K USD | 15.1K USD | 15.76K USD |
| Depreciation and amortization | 771.44M USD | — | 27.39K USD | 44.67K USD | 41.24K USD |
| Operating income | −9.36M USD | −10.56M USD | −20.9M USD | −14.42M USD | −15.77M USD |
| Net income | −9.84M USD | −10.57M USD | −20.66M USD | −14.29M USD | −15.71M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
